HUE063460T2 - Retinitis pigmentosa génterápia - Google Patents

Retinitis pigmentosa génterápia

Info

Publication number
HUE063460T2
HUE063460T2 HUE19186929A HUE19186929A HUE063460T2 HU E063460 T2 HUE063460 T2 HU E063460T2 HU E19186929 A HUE19186929 A HU E19186929A HU E19186929 A HUE19186929 A HU E19186929A HU E063460 T2 HUE063460 T2 HU E063460T2
Authority
HU
Hungary
Prior art keywords
gene therapy
retinitis pigmentosa
pigmentosa
retinitis
therapy
Prior art date
Application number
HUE19186929A
Other languages
English (en)
Inventor
Catherine O'riordan
Matthew Adamowicz
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52829343&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE063460(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of HUE063460T2 publication Critical patent/HUE063460T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2330/00—Production
    • C12N2330/50—Biochemical production, i.e. in a transformed host cell
    • C12N2330/51—Specially adapted vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HUE19186929A 2014-03-21 2015-03-20 Retinitis pigmentosa génterápia HUE063460T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461969027P 2014-03-21 2014-03-21

Publications (1)

Publication Number Publication Date
HUE063460T2 true HUE063460T2 (hu) 2024-01-28

Family

ID=52829343

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE19186929A HUE063460T2 (hu) 2014-03-21 2015-03-20 Retinitis pigmentosa génterápia
HUE15716232A HUE046454T2 (hu) 2014-03-21 2015-03-20 Retinitis pigmentosa génterápia

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE15716232A HUE046454T2 (hu) 2014-03-21 2015-03-20 Retinitis pigmentosa génterápia

Country Status (36)

Country Link
US (3) US10383953B2 (hu)
EP (3) EP3628334B1 (hu)
JP (3) JP6669664B2 (hu)
KR (2) KR20160127832A (hu)
CN (2) CN115252823A (hu)
AR (1) AR099837A1 (hu)
AU (2) AU2015230942B2 (hu)
CA (1) CA2943185A1 (hu)
CL (1) CL2016002333A1 (hu)
CR (1) CR20160480A (hu)
DK (2) DK3119437T3 (hu)
DO (1) DOP2016000237A (hu)
EA (1) EA201691891A1 (hu)
EC (1) ECSP16083000A (hu)
ES (2) ES2957840T3 (hu)
FI (1) FI3628334T3 (hu)
HR (2) HRP20231077T1 (hu)
HU (2) HUE063460T2 (hu)
IL (3) IL247543B (hu)
LT (2) LT3119437T (hu)
MA (1) MA39390B2 (hu)
MX (2) MX2016012201A (hu)
MY (1) MY190726A (hu)
NZ (1) NZ724622A (hu)
PE (1) PE20161252A1 (hu)
PH (1) PH12016501684A1 (hu)
PL (2) PL3119437T3 (hu)
PT (2) PT3119437T (hu)
RS (2) RS64611B1 (hu)
SG (3) SG10201912968WA (hu)
SI (2) SI3628334T1 (hu)
TW (2) TWI780401B (hu)
UA (1) UA120050C2 (hu)
UY (1) UY36044A (hu)
WO (1) WO2015143418A2 (hu)
ZA (1) ZA201605924B (hu)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI3628334T3 (fi) * 2014-03-21 2023-09-15 Genzyme Corp Geenihoito verkkokalvon pigmenttirappeuma
US10450563B2 (en) 2015-02-10 2019-10-22 Genzyme Corporation Variant RNAi
CN108472390B (zh) 2015-12-03 2022-04-15 弗里德里克·米谢尔生物医学研究所 SynP162,用于基因在视杆光感受器中特异性表达的启动子
CN108474001B (zh) * 2015-12-03 2022-04-08 弗里德里克·米谢尔生物医学研究所 SynP160，用于基因在视杆光感受器中特异性表达的启动子
ES2872798T3 (es) 2015-12-04 2021-11-02 Univ Sorbonne Promotores y usos de los mismos
JP7272795B2 (ja) * 2016-03-01 2023-05-12 ユニバーシティ オブ フロリダ リサーチ ファンデーション インコーポレーティッド 優性網膜色素変性の治療のためのａａｖベクター
KR20190039703A (ko) * 2016-07-05 2019-04-15 더 존스 홉킨스 유니버시티 Crispr/cas9-기반 조성물 및 망막 변성을 치료하기 위한 방법
WO2019060726A1 (en) * 2017-09-22 2019-03-28 Genzyme Corporation VARIANT OF ARNI
CA3077380A1 (en) * 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. Methods, compositions, and implantable elements comprising active cells
CN107961380B (zh) * 2017-11-23 2020-05-05 清华大学 试剂在制备药物中的用途、筛选药物的方法以及药物组合物
EP3768327A4 (en) * 2018-03-23 2022-04-13 The Trustees of Columbia University in the City of New York GENE EDIT FOR AUTOSOMAL DOMINANT DISEASES
AU2019276645A1 (en) * 2018-06-01 2020-11-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of dominant retinitis pigmentosa
CN111518813B (zh) * 2019-02-03 2023-04-28 武汉纽福斯生物科技有限公司 视紫红质的编码序列、其表达载体构建及其应用
WO2020180886A1 (en) * 2019-03-04 2020-09-10 The Trustees Of The University Of Pennsylvania Neuroprotective gene therapy targeting the akt pathway
AU2020240136A1 (en) * 2019-03-21 2021-09-30 Ptc Therapeutics, Inc. Vector and method for treating angelman syndrome
KR102396200B1 (ko) * 2020-07-24 2022-05-12 알지노믹스 주식회사 로돕신 전사체에 특이적인 트랜스-스플라이싱 라이보자임 및 이의 용도

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5985583A (en) * 1992-06-23 1999-11-16 Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
ES2308989T3 (es) 1999-08-09 2008-12-16 Targeted Genetics Corporation Aumento de la expresion de una secuencia nucleotidica heterologa a partir de vectores viricos recombinantes que contienen una secuencia que forman pares de bases intracatenarios.
CA2410828C (en) 2000-06-01 2012-01-24 University Of North Carolina At Chapel Hill Duplexed parvovirus vectors
ATE520707T1 (de) 2001-11-13 2011-09-15 Univ Pennsylvania Verfahren für den nachweis und/oder die identifikation von sequenzen des adeno- assoziierten virus (aav) sowie isolation von dadurch identifizierten, neuen sequenzen
JP4999330B2 (ja) * 2004-01-22 2012-08-15 株式会社ディナベック研究所 サイトメガロウイルスエンハンサーおよびニワトリβ−アクチンプロモーターを含むハイブリッドプロモーターを利用したマイナス鎖ＲＮＡウイルスベクターの製造方法
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
CA2683469C (en) 2007-04-12 2019-11-26 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Genetic suppression and replacement
US20090214478A1 (en) * 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
US8734809B2 (en) * 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
WO2011029903A1 (en) * 2009-09-10 2011-03-17 Flemming Velin Method for the preparation of micro-rna and its therapeutic application
EP2529020B1 (en) 2010-01-28 2018-04-25 The Children's Hospital of Philadelphia A scalable manufacturing platform for viral vector purification and viral vectors so purified for use in gene therapy
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
CN107828820B (zh) * 2010-10-27 2022-06-07 学校法人自治医科大学 用于向神经***细胞导入基因的腺相关病毒粒子
PL2675902T3 (pl) 2011-02-17 2019-08-30 The Trustees Of The University Of Pennsylvania Kompozycje i sposoby do zmieniania specyficzności względem tkanki i poprawy transferu genu z udziałem aav9
JP5884152B2 (ja) 2011-07-29 2016-03-15 シャープ株式会社 基地局、端末、通信システムおよび通信方法
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
US20150111955A1 (en) * 2012-02-17 2015-04-23 The Children's Hospital Of Philadelphia Aav vector compositions and methods for gene transfer to cells, organs and tissues
EP2833892A4 (en) * 2012-04-02 2016-07-20 Moderna Therapeutics Inc MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
PT2800811T (pt) * 2012-05-25 2017-08-17 Univ California Métodos e composições para modificação de adn alvo dirigida por arn e para modulação dirigida por arn de transcrição
CN105120901A (zh) 2012-07-11 2015-12-02 宾夕法尼亚大学托管会 Rpgr x染色体连锁视网膜退化的aav介导的基因治疗
US9512425B2 (en) * 2012-10-23 2016-12-06 Cornell University Inhibiting migration of cancer cells
CA2924743A1 (en) 2013-10-04 2015-04-09 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
FI3628334T3 (fi) 2014-03-21 2023-09-15 Genzyme Corp Geenihoito verkkokalvon pigmenttirappeuma

Also Published As

Publication number Publication date
DK3119437T3 (da) 2019-12-09
BR112016021017A2 (pt) 2017-10-03
TWI706789B (zh) 2020-10-11
ZA201605924B (en) 2017-09-27
SG10201912968WA (en) 2020-02-27
MX2016012201A (es) 2017-01-19
CN106456660A (zh) 2017-02-22
EP3628334A1 (en) 2020-04-01
IL284741A (en) 2021-08-31
AR099837A1 (es) 2016-08-24
ES2760263T3 (es) 2020-05-13
TW202021627A (zh) 2020-06-16
CL2016002333A1 (es) 2017-05-26
RS59634B1 (sr) 2020-01-31
PE20161252A1 (es) 2016-11-30
KR20230006039A (ko) 2023-01-10
PL3628334T3 (pl) 2023-12-18
MY190726A (en) 2022-05-12
PL3119437T3 (pl) 2020-04-30
LT3119437T (lt) 2019-12-27
UY36044A (es) 2015-10-30
AU2015230942A1 (en) 2016-10-13
UA120050C2 (uk) 2019-09-25
ECSP16083000A (es) 2017-02-24
SI3628334T1 (sl) 2023-11-30
SG11201607005UA (en) 2016-09-29
AU2021200988A1 (en) 2021-03-11
TWI780401B (zh) 2022-10-11
EP3119437A2 (en) 2017-01-25
MA39390B2 (fr) 2022-04-29
NZ762841A (en) 2023-11-24
EP3628334B1 (en) 2023-06-28
US20200046851A1 (en) 2020-02-13
US20220054657A1 (en) 2022-02-24
PT3628334T (pt) 2023-09-26
HRP20192141T1 (hr) 2020-02-21
US10383953B2 (en) 2019-08-20
HUE046454T2 (hu) 2020-03-30
DOP2016000237A (es) 2016-10-16
JP7048563B2 (ja) 2022-04-05
EA201691891A1 (ru) 2017-01-30
TW201622752A (zh) 2016-07-01
HRP20231077T1 (hr) 2023-12-22
PT3119437T (pt) 2019-12-12
IL284741B (en) 2022-10-01
CR20160480A (es) 2016-12-14
MX2020010694A (es) 2020-11-06
IL275918B (en) 2021-07-29
WO2015143418A3 (en) 2015-11-19
PH12016501684A1 (en) 2016-10-03
WO2015143418A2 (en) 2015-09-24
JP2022084810A (ja) 2022-06-07
KR20160127832A (ko) 2016-11-04
IL284741B2 (en) 2023-02-01
AU2015230942B2 (en) 2020-11-19
FI3628334T3 (fi) 2023-09-15
CN106456660B (zh) 2022-05-31
ES2957840T3 (es) 2024-01-26
IL247543A0 (en) 2016-11-30
EP3119437B1 (en) 2019-09-04
JP2017509632A (ja) 2017-04-06
US11103598B2 (en) 2021-08-31
CA2943185A1 (en) 2015-09-24
IL247543B (en) 2020-07-30
MA39390A1 (fr) 2017-12-29
NZ724622A (en) 2022-05-27
SI3119437T1 (sl) 2020-01-31
JP2020059737A (ja) 2020-04-16
IL275918A (en) 2020-08-31
US20170173183A1 (en) 2017-06-22
JP6669664B2 (ja) 2020-03-18
RS64611B1 (sr) 2023-10-31
EP4345165A2 (en) 2024-04-03
SG10201808218YA (en) 2018-10-30
LT3628334T (lt) 2023-09-25
DK3628334T3 (da) 2023-10-02
CN115252823A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
IL284741A (en) Gene therapy for retinitis pigmentosa
HK1250727A1 (zh) 視網膜色素變性的治療
IL284577A (en) Garden healing
LT3191139T (lt) Pigmentiniam retinitui skirta rpgr genų terapija
GB201407322D0 (en) Gene therapy
GB201707212D0 (en) Gene therapy for ciliopathies
GB201513151D0 (en) Functional gene replacement therapy
IL263085A (en) Garden healing
GB201616821D0 (en) Gene therapy
GB201612105D0 (en) Gene therapy
GB201612104D0 (en) Gene therapy
GB201410595D0 (en) Factor IX gene therapy